NAME OF DRUG MECHANISIM OF INDICATION CONTRAINDICATIO ADVERSE EFFECTS NURSING

ACTION N CONSIDERATIONS

Brand Name: ARIXTRA is the first  Severe renal Spinal or epidural  Use with
Arixtra and only synthetic ARIXTRA is impairment hematomas, which caution in patients
Factor Xa inhibitor, indicated for the (creatinine clearance may result in long- who have
Generic Name: representing an prophylaxis of deep <30 mL/min) in term or permanent conditions or who
fondaparinux important vein thrombosis prophylaxis or paralysis, can occur are taking
evolution in (DVT), which may treatment of venous with the use of concomitant
Dose: 7.5 mg/dose antithrombotic lead to pulmonary thromboembolism. anticoagulants and medications that
embolism (PE) in  Active major neuroaxial increase risk of
Strength therapy. While
patients undergoing: bleeding. (spinal/epidural) hemorrhage.
Description: 12.5 other
 Bacterial anesthesia or spinal  Bleeding risk is
mg/mL antithrombotics
 hip fracture endocarditis. puncture. The risk increased in renal
may inhibit  of these events may impairment and in
surgery,
Route: multiple factors in including Thrombocytopenia be higher with post- patients with low
subcutaneous the coagulation extended associated with a operative use of body weight <50
cascade, ARIXTRA prophylaxis; positive in vitro test indwelling epidural kg.
selectively inhibits  hip for anti-platelet catheters or 
only Factor Xa. replacement antibody in the concomitant use of Thrombocytopenia
surgery; presence of other drugs can occur with
 knee fondaparinux affecting administration of
replacement sodium. hemostasis such as ARIXTRA.
surgery;  Body weight NSAIDs.  Periodic routine
 abdominal <50 kg (venous complete blood
surgery who thromboembolism counts (including
are at risk for prophylaxis only). platelet counts),
thromboembo serum creatinine
lic level, and stool
complications occult blood tests
. are recommended.
 The packaging
Treatment of Acute (needle guard)
 Deep Vein contains dry natural
Thrombosis rubber and may
ARIXTRA is indicated cause allergic
for the treatment of reactions in latex
acute deep vein sensitive
thrombosis when individuals.
administered in
conjunction with
warfarin sodium.

Treatment of Acute
Pulmonary
Embolism
ARIXTRA is indicated
for the treatment of
acute pulmonary
embolism when
administered in
conjunction with
warfarin sodium
when initial therapy
is administered in
the hospital.

NAME OF DRUG MECHANISIM OF INDICATION CONTRAINDICATIO ADVERSE EFFECTS NURSING

ACTION N CONSIDERATIONS
Brand Name: Clopidogrel (Plavix) is Bleeding, including -Avoid concomitant
clopiderguel an inhibitor of For patients with PLAVIX is life-threatening and use of PLAVIX and
platelet aggregation. non-ST-segment contraindicated in fatal bleeding, is drugs that inhibit
Generic Name: A variety of drugs elevation ACS patients with active the most commonly CYP2C19 activity. Co-
plavix that inhibit platelet [unstable angina pathological reported adverse administration of
function have been (UA)/non-ST- bleeding such as PLAVIX with
reaction.
shown to decrease elevation myocardial peptic ulcer or omeprazole, a proton
Dose: morbid events in infarction (NSTEMI)] pump inhibitor that is
intracranial
people with including patients hemorrhage. an inhibitor of
Route established who are to be CYP2C19, reduces the
atherosclerotic managed medically PLAVIX is pharmacological
cardiovascular and those who are to contraindicated in activity of PLAVIX if
disease as evidenced be managed with patients with given concomitantly
by stroke or transient coronary or if given 12 hours
hypersensitivity (eg,
ischemic attacks, revascularization, apart.
anaphylaxis) to
myocardial infarction, PLAVIX has been
clopidogrel or any
or need for bypass or shown to decrease -Thienopyridines,
component of the
angioplasty. This the rate of a including PLAVIX,
product.
indicates that combined end point increase the risk of
platelets participate of cardiovascular bleeding. If a patient
in the initiation death, myocardial is to undergo surgery
and/or evolution of infarction (MI), or and an antiplatelet
these events and that stroke as well as the effect is not desired,
inhibiting them can rate of a combined discontinue PLAVIX 5
reduce the event end point of days prior to surgery.
rate. cardiovascular death,
MI, stroke, or
refractory ischemia.

NAME OF DRUG MECHANISIM OF INDICATION CONTRAINDICATIO ADVERSE EFFECTS NURSING

 ACTION N CONSIDERATIONS

Brand Name: Olmetec, a specific For the treatment of Benicar is Dizziness. Female patients of
olmetec angiotensin II type 1 hypertension contraindicated in childbearing age
Generic Name: antagonist, is used patients who are should be told about
Olmesartan alone or with other hypersensitive to any the consequences of
Dose: antihypertensive component of this second and third
agents to treat product. trimester exposure to
hypertension. Unlike drugs that act on the
Route:
the angiotensin renin-angiotensin
receptor antagonist system and they
losartan, olmesartan should be told also
does not have an that these
active metabolite or consequences do not
possess uricosuric appear to have
effects. Blockade of resulted from
the angiotensin II intrauterine drug
receptor inhibits the exposure that has
negative regulatory been limited to the
feedback of first trimester. These
angiotensin II on patients should be
renin secretion, but asked to report
the resulting pregnancies to their
increased plasma physicians as soon as
renin activity and possible.
circulating
angiotensin II levels
do not overcome the
effect of olmesartan
on blood pressure.